 Ramipril
"Ramipril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
| Descriptor ID |
D017257
|
| MeSH Number(s) |
D03.605.084.750
|
| Concept/Terms |
Vesdil- Vesdil
- AstraZeneca Brand of Ramipril
- Promed Brand of Ramipril
Carasel- Carasel
- Almirall Brand of Ramipril
Triatec- Triatec
- Altace
- Delix
- Ramace
- Monarch Brand of Ramipril
- Zabien
- Aventis Brand of Ramipril
- Hoechst Brand of Ramipril
- Aventis Pharma Brand of Ramipril
- Astra Brand of Ramipril
- Acovil
- Tritace
|
Below are MeSH descriptors whose meaning is more general than "Ramipril".
Below are MeSH descriptors whose meaning is more specific than "Ramipril".
This graph shows the total number of publications written about "Ramipril" by people in this website by year, and whether "Ramipril" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Ramipril" by people in Profiles.
-
Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013 Sep; 23(9):470-8.
-
Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug; 27(8):479-86.
-
Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller ER, Rostand S, Toto R, Wang X, Wright JT, Appel LJ. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
-
Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008 Aug 16; 372(9638):511-2.
-
Appel LJ, Wright JT, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008 Apr 28; 168(8):832-9.
-
Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, Smith DW, Bakris GL, Middleton JP, Norris KC, Wright JT, Cheek D, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
-
Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85.
-
Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
-
Fox JC, Leight K, Sutradhar SC, Demopoulos LA, Gleim GW, Lewin AJ, Bakris GL. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
-
Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|